Endocannabinoids in liver disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hepatology

• Publication date

  2011-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.24077PMID 21254182PMCID PMC3073545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease.

  2010cited by this paper
• Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-γ*

  2010cited by this paper
• Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration

  2010cited by this paper
• Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.

  2010influential reference
• Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

  2010cited by this paper
• Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis

  2010cited by this paper
• CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice

  2010cited by this paper
• CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance.

  2010cited by this paper
• Anandamide induces cell death through lipid rafts in hepatic stellate cells

  2010cited by this paper
• Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

  2010cited by this paper
• Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.

  2009cited by this paper
• Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways*

  2009cited by this paper
• Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A

  2009cited by this paper
• Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia–reperfusion injury complicated by endotoxaemia

  2009cited by this paper
• Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis

  2009cited by this paper
• Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.

  2009cited by this paper
• Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.

  2009cited by this paper
• Role of the Endocannabinoid System in Abdominal Obesity and the Implications for Cardiovascular Risk

  2009cited by this paper
• Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.

  2009cited by this paper
• Circulating and hepatic endocannabinoids and endocannabinoid‐related molecules in patients with cirrhosis

  2009cited by this paper
• Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis

  2009cited by this paper
• Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins

  2008cited by this paper
• Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats

  2008cited by this paper
• Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.

  2008cited by this paper
• Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells

  2008influential reference
• CB2 receptors as new therapeutic targets for liver diseases

  2008cited by this paper
• Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats

  2008cited by this paper
• Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

  2008cited by this paper
• Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation.

  2008cited by this paper
• Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

  2008cited by this paper
• Gastrointestinal , Hepatobiliary and Pancreatic Pathology Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Nonalcoholic Steatohepatitis

  2008cited by this paper
• Anandamide Biosynthesis Catalyzed by the Phosphodiesterase GDE1 and Detection of Glycerophospho-N-acyl Ethanolamine Precursors in Mouse Brain*

  2008cited by this paper
• Cannabinoids and Capsaicin Improve Liver Function Following Thioacetamide-Induced Acute Injury in Mice

  2008cited by this paper
• Pivotal Advance: Cannabinoid‐2 receptor agonist HU‐308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

  2007cited by this paper
• Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.

  2007cited by this paper
• CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis

  2007cited by this paper
• Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury

  2007cited by this paper
• Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP‐activated protein kinase

  2007cited by this paper
• Role of cannabinoid CB2 receptors in glucose homeostasis in rats.

  2007cited by this paper
• Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

  2007cited by this paper
• CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.

  2007cited by this paper
• The endocannabinoid 2‐arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species

  2007cited by this paper
• Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.

  2007cited by this paper
• Role of Ca2+‐dependent potassium channels in in vitro anandamide‐mediated mesenteric vasorelaxation in rats with biliary cirrhosis

  2007cited by this paper
• Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease

  2007cited by this paper
• Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain.

  2007cited by this paper
• The Pharmacology of the Cannabinoid System—A Question of Efficacy and Selectivity

  2007cited by this paper
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

  2006cited by this paper
• Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats

  2006cited by this paper
• Neuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity

  2006cited by this paper
• Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

  2006cited by this paper
• Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors

  2006cited by this paper
• A biosynthetic pathway for anandamide

  2006cited by this paper
• CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

  2006cited by this paper
• Therapy Insight: cirrhotic cardiomyopathy

  2006cited by this paper
• The emerging role of the endocannabinoid system in endocrine regulation and energy balance.

  2006cited by this paper
• Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.

  2006influential reference
• Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice.

  2006cited by this paper
• Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.

  2006cited by this paper
• Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome.

  2005cited by this paper
• Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP.

  2005cited by this paper
• Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors

  2005influential reference
• Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis

  2005cited by this paper
• Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct‐ligated rats

  2005cited by this paper
• Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C

  2005cited by this paper
• Structure and function of fatty acid amide hydrolase.

  2005cited by this paper
• The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile

  2005cited by this paper
• Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

  2005cited by this paper
• Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

  2005cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

  2005influential reference
• Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1 Coactivation of SREBP

  2005cited by this paper
• Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice

  2005cited by this paper
• Cannabinoid receptor signaling.

  2005cited by this paper
• Evidence for novel cannabinoid receptors.

  2005cited by this paper
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  2005cited by this paper
• Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis

  2004cited by this paper
• CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

  2004cited by this paper
• The role of AMP-activated protein kinase in the action of ethanol in the liver.

  2004cited by this paper
• Vasodilator mRNA levels are increased in the livers of portal hypertensive NO‐synthase 3‐deficient mice

  2004cited by this paper
• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

  2003cited by this paper
• HGF-, EGF-, and dexamethasone-induced gene expression patterns during formation of tissue in hepatic organoid cultures.

  2003cited by this paper
• Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF-κB Independently of Platelet-activating Factor*

  2003cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Potentiation of Anandamide Effects in Mesenteric Beds Isolated from Endotoxemic Rats

  2003influential reference
• Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

  2002cited by this paper
• Brain monoglyceride lipase participating in endocannabinoid inactivation

  2002cited by this paper
• Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein (SREBP)*

  2002cited by this paper
• Renal sodium retention in preascitic cirrhosis: Expanding knowledge, enduring uncertainties

  2002cited by this paper
• Systemic and portal hemodynamic effects of anandamide.

  2001cited by this paper
• Leptin-regulated endocannabinoids are involved in maintaining food intake

  2001cited by this paper
• Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.

  2001cited by this paper
• Overfeeding rapidly induces leptin and insulin resistance.

  2001cited by this paper
• Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

  2001cited by this paper
• Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity.

  2000cited by this paper
• Polymyxin B binds to anandamide and inhibits its cytotoxic effect

  2000cited by this paper
• Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

  2000cited by this paper
• Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons.

  2000cited by this paper
• Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

  1999cited by this paper
• Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.

  1999cited by this paper

• Cannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis

  2026cites this paper
• Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.

  2026cites this paper
• Changes of CB1 Receptor Expression in Tissues of Cocaine-Exposed Eels

  2025cites this paper
• Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold

  2025cites this paper
• The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review

  2025influential citation
• Distribution of endocannabinoid system receptors in the equine hoof: dysregulation as a potential therapeutic target for laminitis

  2025cites this paper
• Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation

  2025cites this paper
• Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases

  2025cites this paper
• The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology

  2025cites this paper
• Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic Syndrome

  2025cites this paper
• The impact of cannabinoid receptor 1 absence on mouse liver mitochondria homeostasis: insight into mitochondrial unfolded protein response

  2024cites this paper
• Immunometabolic chaos in septic shock

  2024cites this paper
• Hepatoprotective Effect of Cannabidiol on the Progression of Experimental Hepatic Cirrhosis in Rats

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• Association of Cannabis Use with Complications Among Patients with Gastroesophageal Reflux Disease: Insights from National Inpatient Sample

  2024cites this paper
• The influence of Akkermansia muciniphila on intestinal barrier function

  2024cites this paper
• DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry.

  2023cites this paper
• The progress of autoimmune hepatitis research and future challenges

  2023cites this paper
• Effects of Full-Spectrum Cannabis Oil with a Cannabidiol:Tetrahydrocannabinol 2:1 Ratio on the Mechanisms Involved in Hepatic Steatosis and Oxidative Stress in Rats Fed a Sucrose-Rich Diet

  2023cites this paper
• Nutritional intervention is promising in alleviating liver injury during tuberculosis treatment: a review

  2023cites this paper
• Cannabinoids as Potential Therapeutic Agents for Kidney and Liver Toxicity

  2023cites this paper
• The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives

  2022cites this paper
• Marijuana-Induced Acute Hepatitis: A Case Report

  2022cites this paper
• Folic acid protects against tuberculosis-drug-induced liver injury in rats and its potential mechanism by metabolomics.

  2022cites this paper
• Patient Evaluation: Precautions and Managing Expectations

  2022cites this paper
• Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor

  2022cites this paper
• (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  2022cites this paper
• The effects of subacute exposure to a water-soluble cannabinol compound in male mice

  2022cites this paper
• Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes

  2022cites this paper
• Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease

  2021influential citation
• Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis

  2021cites this paper
• The Potential Use of Cannabis in Tissue Fibrosis

  2021cites this paper
• 1-Methyl tryptophan, an indoleamine 2,3-dioxygenase inhibitor, attenuates cardiac and hepatic dysfunction in rats with biliary cirrhosis.

  2021cites this paper
• Omega‐3 phospholipids and obesity‐associated NAFLD: Potential mechanisms and therapeutic perspectives

  2021cites this paper
• Cannabinoid receptor-1 signaling in hepatocytes and stellate cells does not contribute to NAFLD.

  2021cites this paper
• Metabolic Consequences of Gestational Cannabinoid Exposure

  2021cites this paper
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases

  2021cites this paper
• Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment

  2021cites this paper
• Hepatic Cannabinoid Signaling in the Regulation of Alcohol-Associated Liver Disease

  2021influential citation
• The endocannabinoid system in the adipose organ

  2021cites this paper
• Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility

  2021cites this paper
• Omega‐3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non‐alcoholic fatty liver disease

  2021cites this paper
• Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell

  2020cites this paper
• Tissue Fibrosis, Aging and the Potential Use of Cannabinoids as Anti-Fibrotic Agents

  2020cites this paper
• The therapeutic potential of second and third generation CB1R antagonists.

  2020cites this paper
• Exacerbated LPS/GalN-Induced Liver Injury in the Stress-Sensitive Wistar Kyoto Rat Is Associated with Changes in the Endocannabinoid System

  2020cites this paper
• CB2R agonist JWH-133 attenuates chronic inflammation by restraining M1 macrophage polarization via Nrf2/HO-1 pathway in diet-induced obese mice.

  2020cites this paper
• New aspects of hepatic endothelial cells in physiology and non-alcoholic fatty liver disease.

  2020cites this paper
• Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent

  2020cites this paper
• Different Effects of Cannabis Abuse on Adolescent and Adult Brain

  2020cites this paper
• Reply to: Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C.

  2020cites this paper
• Hydrodynamics-based liver transfection achieves gene silencing of CB1 using short hairpin RNA plasmid in cirrhotic rats

  2020cites this paper
• Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort)

  2020cites this paper
• Dynamic changes of key metabolites during liver fibrosis in rats

  2019cites this paper
• Association Between Cannabis Use and Complications Related to Crohn’s Disease: A Retrospective Cohort Study

  2019cites this paper
• Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.

  2019cites this paper
• Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary

  2019cites this paper
• Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis

  2019influential citation
• Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis

  2019cites this paper
• Nanomedicine: A New Therapeutic Approach in Liver Diseases

  2019cites this paper
• Cannabis and the liver: Things you wanted to know but were afraid to ask.

  2019cites this paper
• Stress during Lactation Induces Insulin Resistance Associated with an Increase in Type 1 Cannabinoid Receptors in Liver and Adipose Tissue

  2019cites this paper
• Dietary fatty acids and bioactive fatty acid metabolites in alcoholic liver disease

  2019cites this paper
• The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease

  2019cites this paper
• The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms

  2019cites this paper
• β‐Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice

  2018cites this paper
• Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics

  2018cites this paper
• History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist

  2018cites this paper
• Reduced Prevalence of Alcoholic Gastritis in Hospitalized Individuals Who Consume Cannabis

  2018cites this paper
• Hepatic microcirculation and mechanisms of portal hypertension

  2018cites this paper
• Effects of high-fat diet and age on the blood lipidome and circulating endocannabinoids of female C57BL/6 mice.

  2018cites this paper
• Human Liver Fatty Acid Binding Protein-1 T94A Variant, Nonalcohol Fatty Liver Disease, and Hepatic Endocannabinoid System.

  2018cites this paper
• Structural and Functional Interaction of Δ9-Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1).

  2018cites this paper
• The endocannabinoid‐alcohol crosstalk: Recent advances on a bi‐faceted target

  2018cites this paper
• Scp-2/Scp-x ablation in Fabp1 null mice differentially impacts hepatic endocannabinoid level depending on dietary fat.

  2018cites this paper
• Impact of Fabp1 Gene Ablation on Uptake and Degradation of Endocannabinoids in Mouse Hepatocytes.

  2018cites this paper
• PPAR&agr;/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models

  2018cites this paper
• Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.

  2018cites this paper
• Δ9-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by Fabp1 gene ablation

  2018cites this paper
• Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease

  2018cites this paper
• CB1 & CB2 Receptor Pharmacology

  2018cites this paper
• CB2R agonist prevents nicotine induced lung fibrosis

  2018cites this paper
• Endocannabinoids in Body Weight Control

  2018cites this paper
• Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease

  2018influential citation
• Endogenous regulation of brown adipose tissue in humans

  2018cites this paper
• Mental Health in Chronic and End-Stage Liver Disease

  2018cites this paper
• Modulation of inflammation in the reduction of intra hepatic resistance

  2018cites this paper
• Effect of maternal high-fat diet on key components of the placental and hepatic endocannabinoid system.

  2018cites this paper
• The Role of Cannabinoids in the Setting of Cirrhosis

  2018influential citation
• Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.

  2018cites this paper
• Loss of toll-like receptor 3 aggravates hepatic inflammation but ameliorates steatosis in mice.

  2018cites this paper
• Cannabinoid Receptor 1 Participates in Liver Inflammation by Promoting M1 Macrophage Polarization via RhoA/NF-κB p65 and ERK1/2 Pathways, Respectively, in Mouse Liver Fibrogenesis

  2017cites this paper
• Hepatorenal Syndrome-Current Concepts in Pathophysiology

  2017cites this paper
• Hepatic expressions of cannabinoid receptors CB 1 and CB 2 correlate with the fibrogenesis in patients with chronic hepatitis B

  2017cites this paper
• Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.

  2017cites this paper
• Cannabinoids Receptors in Liver: Diet and Physiopathology

  2017cites this paper
• Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

  2017cites this paper
• A TWO-STAGE GENOME-WIDE ASSOCIATION STUDY CONFIRMS PNPLA 3 AND IDENTIFIES TM 6 SF 2 AND MBOAT 7 AS RISK LOCI FOR ALCOHOL-RELATED CIRRHOSIS

  2017cites this paper
• 4-O′-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice

  2017cites this paper